5932-30-9

Usage

Uses

Used in Pharmaceutical Industry:
5-Phenyl-pyrazole-3-carboxylic acid ethyl ester is used as a building block for the synthesis of various biologically active compounds due to its antimicrobial, antitumor, and anti-inflammatory properties. It serves as a crucial intermediate in the development of new drugs that target a range of health conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Phenyl-pyrazole-3-carboxylic acid ethyl ester is utilized as a precursor in the creation of compounds with pesticidal properties, contributing to the development of effective and novel agrochemicals for crop protection and enhancement of agricultural yields.
Used in Material Science:
5-Phenyl-pyrazole-3-carboxylic acid ethyl ester is also studied for its potential use in the development of new materials, where its unique chemical structure may offer novel properties and applications in various material technologies.
Used in Chemical Research:
As a tool in chemical research, 5-Phenyl-pyrazole-3-carboxylic acid ethyl ester aids in exploring new chemical reactions and mechanisms, potentially leading to advancements in synthetic methodologies and the discovery of new chemical entities with diverse applications.

InChI:InChI=1/C12H12N2O2/c1-2-16-12(15)11-8-10(13-14-11)9-6-4-3-5-7-9/h3-8H,2H2,1H3,(H,13,14)

Upstream product

• 623-73-4 diazoacetic acid ethyl ester 
• 536-74-3 phenylacetylene 
• 6296-54-4 ethyl 2,4-dioxo-4-phenylbutyrate 
• 5071-61-4 5-phenyl-1H-pyrazole-3-carboxylic acid 
• 141-52-6 sodium ethanolate 
• 94274-67-6 tert-Butylammonium- 
• 75-64-9 tert-butylamine 
• 122-78-1 phenylacetaldehyde 
• 88330-79-4 2-hydroxy-4-oxo-4-phenylbut-2-enoic acid ethyl ester 
• 588-72-7 [(E)-2-bromoethenyl]benzene 
• 100-42-5 styrene 
• 7063-99-2 ethyl 5-phenylisoxazole-3-carboxylate 
• 98-86-2 acetophenone 
• 95-92-1 oxalic acid diethyl ester 

Downstream Products

• 179057-19-3 (5-phenyl-1H-pyrazol-3-yl)methanol 
• 5071-61-4 5-phenyl-1H-pyrazole-3-carboxylic acid 
• 952191-72-9 ethyl 1-[(4-methylphenyl)sulfonyl]-5-phenyl-1H-pyrazole-3-carboxylate 
• 1403947-53-4 C₁₉H₂₅N₃O₃ 
• 1403947-52-3 C₁₉H₂₅N₃O₃ 
• 1403947-55-6 C₁₇H₂₁N₃O₃ 
• 1403946-40-6 C₂₄H₂₅F₃N₄O₂ 
• 1186640-10-7 C₁₂H₁₃N₃O₂ 
• 1291003-54-7 C₁₄H₁₇N₃O₃ 
• 1290678-96-4 C₁₃H₁₅N₃O₂ 
• 1187446-86-1 C₁₃H₁₅N₃O₂ 
• 1446419-26-6 C₁₆H₂₁N₃O₃ 
• 1446450-02-7 C₁₄H₁₇N₃O₄ 
• 1290683-64-5 C₁₃H₁₅N₃O₂ 

Relevant academic research and scientific papers

Generation of Diazomethyl Radicals by Hydrogen Atom Abstraction and Their Cycloaddition with Alkenes

A general catalytic methodology for the synthesis of pyrazolines from α-diazo compounds and conjugated alkenes is reported. The direct hydrogen atom transfer (HAT) process of α-diazo compounds promoted by the tert-butylperoxy radical generates electrophilic diazomethyl radicals, thereby reversing the reactivity of the carbon atom attached with the diazo group. The regiocontrolled addition of diazomethyl radicals to carbon-carbon double bonds followed by intramolecular ring closure on the terminal diazo nitrogen and tautomerization affords a diverse set of pyrazolines in good yields with excellent regioselectivity. This strategy overcomes the limitations of electron-deficient alkenes in traditional dipolar [3+2]-cycloaddition of α-diazo compounds with alkenes. Furthermore, the straightforward formation of the diazomethyl radicals provides umpolung reactivity, thus opening new opportunities for the versatile transformations of diazo compounds.

Discovery of heterocyclic carbohydrazide derivatives as novel selective fatty acid amide hydrolase inhibitors: design, synthesis and anti-neuroinflammatory evaluation

Fatty acid amide hydrolase (FAAH) is a promising target for the development of drugs to treat pain, inflammation, and other central nervous system disorders. Herein, a series of novel heterocyclic carbohydrazide derivatives were firstly designed by the classic scaffold-hopping strategy. Then, multi-steps synthesis and human FAAH enzyme inhibiting activity assays were conducted. Among them, compound 26 showed strong inhibition against human FAAH with IC50 of 2.8 μM. Corresponding docking studies revealed that the acyl hydrazide group of compound 26 well-occupied the acyl-chain binding pocket. It also exhibited high selectivity towards FAAH when comparing with CES2 and MAGL. Additionally, compound 26 effectively suppressed the LPS-induced neuroinflammation of microglial cells (BV2) via the reduction of interleukin-1β and tumor necrosis factor-α. Our results provided significative lead compounds for the further discovery of novel selective and safe FAAH inhibitors with potent anti-neuroinflammation activity.

Design, synthesis and anti-HIV evaluation of 5-alkyl- 6-(benzo[d][1,3]dioxol-5-alkyl)-2-mercaptopyrimidin-4(3H)-ones as potent HIV-1 NNRTIs

In order to discover and develop the new HIV-1 NNRTIs, a series of 5-alkyl-6-(benzo[d][1,3]dioxol-5-ylalkyl)-2-mercaptopyrimidin-4(3H)-ones was synthesized and screened for their in vitro cytotoxicity against HIV-1. Most of the compounds we synthetized sh

Intramolecular Cyclization of Vinyldiazoacetates as a Versatile Route to Substituted Pyrazoles

Vinyldiazo compounds undergo a thermal electrocyclization to form pyrazoles in yields of up to 95percent. The reactions are operationally simple, use readily available starting materials, require no intervention of a catalyst, and enable the synthesis of mono-, di- A nd tri-substituted pyrazoles. With the ability to produce highly substituted pyrazoles and the flexibility in installing various types of substituents, this method constitutes a new entry to this valuable heterocyclic scaffold and may be of interest to all branches of the chemical industry.

PYRIMIDINONE-CONTAINING COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF

Disclosed is a pyrimidinone-containing compound represented by formula I, a preparation method thereof, a pharmaceutical composition, and an application thereof. The pyrimidinone-containing compound of the present disclosure can be used as HIV-1 inhibitor

Discovery of Membrane-Bound Pyrophosphatase Inhibitors Derived from an Isoxazole Fragment

Membrane-bound pyrophosphatases (mPPases) regulate energy homeostasis in pathogenic protozoan parasites and lack human homologues, which makes them promising targets in e.g. malaria. Yet only few nonphosphorus inhibitors have been reported so far. Here, w

Substituted heterocyclic compound containing urea skeleton and preparation method and application of substituted heterocyclic compound

The invention discloses a substituted heterocyclic compound containing a urea skeleton and a preparation method and application of the substituted heterocyclic compound, and relates to the field of pharmaceutical chemistry, in particular to the substituted heterocyclic compound containing the urea skeleton or pharmaceutically acceptable salt of the substituted heterocyclic compound, a pharmaceutical composition containing the compounds and medical application of the compounds. Particularly, the invention relates to application of the substituted heterocyclic compound as an FAAH inhibitor in preparing drugs for preventing or treating diseases associated with FAAH, such as depression, analgesia, cannabinoid using disorders and other related diseases.

FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR

The present invention discloses a five-membered heterocyclic amide WNT pathway inhibitor, which belongs to a compound that regulates the activity of a Wnt signaling pathway, and provides a method for preparing such a compound, and the use of such a compound in preparing a medicament that antagonizes the Wnt signaling pathway. The five-membered heterocyclic amide WNT pathway inhibitor provided by the invention has a remarkable anti-tumor activity based on a target-based rational drug design of, and can be used for the development of a new generation of Wnt pathway inhibitors, and has a great clinical application value and considerable market potential.

COMPOUNDS CAPABLE OF INHIBITING VOLTAGE GATED CALCIUM ION CHANNEL, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

Disclosed herein are an N-(pyrazolylmethyl)arylsulfonamide derivative useful as a calcium ion channel blocker, a pharmaceutically acceptable salt thereof, and the medicinal use thereof as a therapeutic agent using its calcium ion channel blocking effect.